All In Biotech

Drugs by condition

Drugs approved for fabry disease

Brand-name prescription drugs and biologics whose FDA label lists fabry disease as an approved use. Matched on the label phrases: "Fabry".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

3

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

3

New molecular entities and new biologics

In development

7

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for fabry disease.

  • Elfabrio (Pegunigalsidase Alfa-Iwxj) · Chiesi Farmaceutici Spa NovelPriority reviewMay 9, 2023
  • Galafold (Migalastat Hydrochloride) · Amicus Therap US NovelAccelerated approvalPriority reviewOrphanAug 10, 2018
  • Fabrazyme (Agalsidase Beta) · Genzyme NovelAccelerated approvalPriority reviewOrphanApr 24, 2003

All approved drugs for fabry disease, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme (2)

  • Elfabrio Pegunigalsidase Alfa-Iwxj · Chiesi Farmaceutici Spa · 2023
  • Fabrazyme Agalsidase Beta · Genzyme · 2003

Class not listed in FDA's data (1)

  • Galafold Migalastat Hydrochloride · Amicus Therap US · 2018

Drugs in development for fabry disease

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • VenglustatGZ402671Phase 35 trials

    Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1

  • LucerastatPhase 32 trials

    Idorsia Pharmaceuticals Ltd. · Fabry Disease

  • 4D-310Phase 22 trials

    4D Molecular Therapeutics · Fabry Disease

  • AMT-191Phase 21 trial

    UniQure Biopharma B.V. · Fabry Disease

  • EXG110Phase 21 trial

    Guangzhou Jiayin Biotech Ltd · Fabry Disease

  • HM15421GC1134APhase 21 trial

    GC Biopharma Corp · Fabry Disesase

  • ST-920Phase 21 trial

    Sangamo Therapeutics · Fabry Disease

More on fabry disease: recruiting trials · published research

Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Gaucher disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.